Cold-adapted, live attenuated influenza vaccine

References

• Maassab HF. Adaptation and growth characteristics of influenza virus at 25°C. Nature 213, 612–14 (1967).
   PubMed Web of Science ®Google Scholar
• Maassab HF, DeBorde DC. Development and characterization of cold-adapted virus for use as live virus vaccines. Vaccine 3, 355–369 (1985).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Ed), Blackwell Science, Oxford, UK, 373–390 (1998).
   Google Scholar
• •The authors summarize studies of the live attenuated influenza vaccine sponsored by NIAID, NIH, USA that led to development for licensure.
   Google Scholar
• Centers for Disease Control and Prevention. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52(RR-13), 1–8 (2003).
   Google Scholar
• Piedra PA, Glezen WP, Mbawuike I et al Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 11, 718–724 (1993).
   PubMedGoogle Scholar
• Glezen WI? Emerging infections: pandemic influenza. EpidemioL Rev. 18, 64–76 (1996).
   PubMed Web of Science ®Google Scholar
• •This paper provides the rationale for universal immunization of children.
   Google Scholar
• Thompson WW, Shay DK, Weintraub E et al Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52(RR-8), 1–34 (2003).
   Google Scholar
• Centers for Disease Control and Prevention. Update: influenza activity — United States, December 21, 2003—January 3,2004. MMWR 52, 1288–1290 (2004).
   PubMedGoogle Scholar
• Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283, 499–505 (2000).
   Google Scholar
• Neuzil KM, Nellen BG, Wright PF, Mitchell EF, Griffin MR. The effect of influenza on hospitalizations, out-patient visits and courses of antibiotics in children. N EnglJ. Med. 342, 225–231 (2000).
   Google Scholar
• •This paper describes the impact of influenza on healthy children.
   Google Scholar
• Izurieta HS, Thompson WW, Karmarz P et al Influenza and the rates of hospitalization for respiratory disease among infants and young children. N EngL J. Med. 342, 232–239 (2000).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Severe morbidity and mortality associated with influenza in children and young adults. MMWR 52, 837–840 (2003).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Update: influenza-associated deaths reported among children aged 8 years — United States, 2003–2004 influenza season. MMWR 52, 1286–1288 (2004).
   Google Scholar
• Chiu SS, Tse CYC, Lau YL, Peiris M. Influenza A infection is an important cause offebrile seizures. Pediatrics 108(4), E63 (2001).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr. Infect. Dis. J. 16, 1065–1068 (1997).
   Google Scholar
• Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season. Arch. Pediatr. Adolesc. Med. 156, 986–991 (2002).
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Walters MI, Sellman J et al Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin. Infect. Dis. 30, 784–789 (2000).
   PubMed Web of Science ®Google Scholar
• Robinson P, Taylor K, Nolan T Risk-factors for meningococcal disease in Victoria, Australia, in 1997. EpidemioL Infect. 127, 261–268 (2001).
   PubMed Web of Science ®Google Scholar
• Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14 month experience in a pediatric intensive care unit. C/in. Infect. Dis. 27, 458–462 (1998).
   Google Scholar
• Glezen P. Prevention of acute otitis media by prophylaxis and treatment of influenza virus infections. Vaccine 9, S56—S58 (2001).
   Google Scholar
• Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev. Infect. Dis. 2, 408–420 (1980).
   PubMedGoogle Scholar
• Reichert TA, Sugaya N, Fedson DS et at. The Japanese experience with vaccinating school children against influenza. N EngL J. Med. 344, 889–896 (2001).
   Google Scholar
• •Evaluation of the Japanese schoolchildren program of influenza immunizations provides proof of concept for universal influenza immunization of children.
   Google Scholar
• Reichert TA. The Japanese program of vaccination of school children against influenza: implications for control of the disease. Semin. Pediatr. Infect. Dis. 13, 104–111 (2002).
   PubMedGoogle Scholar
• Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children. J. Infect. Dis. 122, 16–25 (1970).
   Google Scholar
• Hurwitz ES, Haber M, Chang A et al. Effectiveness of influenza vaccination of daycare children in reducing influenza-related morbidity among household contacts. JAMA 284, 1677–1682 (2000).
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Slepushkin AN, Monto AS et al. Efficacy of live attenuated and inactivated influenza vaccines in school children and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 168, 881–887 (1993).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N EngL J. Med. 338, 1405–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Oya A, Nerome K. Experience with mass vaccination of young age groups with inactivated vaccines. In: Options for the Control of Influenza. Kendal AP, Patriarcha PA (Eds), Alan R. Liss, Inc., NY, USA, 183–192 (1986).
   Google Scholar
• Hurwitz ES, Haber M, Chang A et al. Studies of the 1996–1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection and clinical effectiveness. J. Infect. Dis. 182, 1218–1221 (2000).
   Google Scholar
• Couch RB, Quarles JM, Cate TR, Zahradnik JM. Clinical trials with live, cold-reassortant influenza virus vaccines. In: Options fir the Control ofInfluenza. Kendal AP, Patriarcha PA (Eds), Alan R. Liss, Inc., NY, USA 223–241 (1986).
   Google Scholar
• Keitel WA, Couch RB, Quarles JM et al. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.' Infect. Dis. 167, 305–11 (1993).
   Web of Science ®Google Scholar
• Mendelman PM, Cordova J, Iksung C. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 19, 2221–2226 (2001).
   Google Scholar
• King JC, Lagos R, Bernstein DI et al Safety and immunogencity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177, 1394–1397 (1998).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Halloran ME, Nizam A et al Estimation of the efficacy of live, attenuated influenza vaccine from a 2 year, multi-center vaccine trial: implications for influenza control. Vaccine 18, 899–906 (2000).
   Web of Science ®Google Scholar
• •Efficacy of CAW-T in young children is reviewed and implications for control of epidemic influenza explored.
   Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.' Pediatr. 136, 168–175 (2000).
   Web of Science ®Google Scholar
• Belshe RB, Gruber WC, Mendelman PM et al Correlates of immune protection induced by live, attenuated cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181, 1133–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, KodoffK, Betts RF et al Evaluation of trivalent, live, cold-arinpted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild type influenza A(H1N1), A(H3N2) and B viruses. Vaccine 18, 899–906 (2000).
   Web of Science ®Google Scholar
• Nichol KL, Mendelman PM, Mallon KP et al Effectiveness of live, attenuated intranasal influenza virus vaccine in health, working adults. JAMA 282, 137–144 (1999).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 21, 2207–2217 (2003).
   PubMed Web of Science ®Google Scholar
• Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effectiveness of the intranasal, live attenuated, trivalent cold-adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. Arch. Pediatr. Adolosc. Med. 158, 65–73 (2004).
   Google Scholar
• Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A(H1N1) and B using surveillance cultures. Am. J. EpidemioL 158, 305-311(2003).
   Google Scholar
• •Demonstrates the use of selective influenza surveillance of a subset of participants in Phase IV trials to calculate adjusted efficacy.
   Google Scholar
• Monto AS. Invited commentary: use of selective viral cultures to adjust nonvirologic end points in studies of influenza vaccine efficacy. Am. J. EpidemioL 158, 312–315 (2003).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Herschler G et al. Safety and effectiveness of the trivalent, cold-adapted influenza (CAIV-T) in children. In: Options for the Control of Influenza /1/,- Osterhaus ADME, Cox N, Hampson AW (Eds). Excerpta Medica, Amsterdam, Holland 939–943 (2001).
   Google Scholar
• Piedra PA, Gaglani MJ, Kozinetz C, Glezen P. Indirect effectiveness (herd immunity) from intranasal cold-adapted influenza vaccine — trivalent (CAIV-T) given to children 1.5 to 18 years of age, 1998–2001. Fifth Annual Conference on Vaccine Research, MD, USA (2002).
   Google Scholar
• Piedra PA. Safety of the trivalent, cold- adpated influenza vaccine (CAIV-T) in children. Semin. Pediatr. Infect. Dis. 13, 90–96 (2002).
   PubMedGoogle Scholar
• Piedra PA, Yan L, Kotloff K et al Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110, 662–672 (2002).
   PubMed Web of Science ®Google Scholar
• Bergen R, Black S, Shinefield H. et al. Safety of cold-adapted live attenuated vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23, 138–144 (2004).
   Google Scholar
• Martinez FD, Wright AL, Taussig LM et al Asthma and wheezing in the first six years of life. N. EngL J. Med 332, 133–138 (1995).
   PubMed Web of Science ®Google Scholar